Recall of six batches of three products “Carbimazole 5 Tab 5mg (Remedica), Remycin 100 Cap 100mg and Methyldopa 250 Tab 250mg (Remedica)”The Department of Health (DH) today (14 August) endorsed a licensed drug wholesaler, Healthcare Pharmascience Limited (HCPS), to recall six batches of three products, namely (i) Carbimazole 5 Tab 5mg (Remedica) (Hong Kong Registration number: HK-52760; batch numbers: 113195, 120776 and 120809); (ii) Remycin 100 Cap 100mg (Hong Kong Registration number: HK-44279; batch number: 117542); and (iii) Methyldopa 250 Tab 250mg (Remedica) (Hong Kong Registration number: HK-43458; batch numbers: 105371 and 113216) from the market due to potential quality issue.The DH received notification from HCPS that the overseas manufacturer of the above products is voluntarily recalling the affected batches because ongoing stability testing results in those batches did not meet the quality specifications. As a precautionary measure, HCPS is voluntarily recalling the affected batches from the market.The above three products contain carbimazole, doxycycline and methyldopa respectively. All three are prescription medicines: carbimazole is used to reduce the formation of thyroid hormones in patients with an overactive thyroid gland, doxycycline to treat bacterial infections, and methyldopa to treat high blood pressure. According to HCPS, the affected batches had been imported into Hong Kong and supplied to private doctors, private hospitals and pharmacies.HCPS has set up a hotline 3472 8102to answer related enquiries.So far, the DH has not received any adverse reaction reports in connection with the products. The DH will closely monitor the recall.Patients who are taking the above product(s) should not stop taking the medicine(s), but should consult their healthcare professionals as soon as possible for appropriate arrangements.

Ends/ Friday, August 14, 2026

回收六個批次共三款產品 「Carbimazole 5 Tab 5mg (Remedica)、 Remycin 100 Cap 100mg 及Methyldopa 250 Tab 250mg (Remedica) 」衞生署今日（八月十四日）同意持牌藥物批發商凱健科研產品有限公司（凱健），從市面回收六個批次共三款產品，包括：(i)「Carbimazole 5 Tab 5mg (Remedica)」（香港註冊編號：HK-52760；批號：113195、120776及120809）；(ii)「Remycin 100 Cap 100mg」（香港註冊編號：HK-44279；批號：117542）；及(iii)「Methyldopa 250 Tab 250mg (Remedica)」（香港註冊編號：HK-43458；批號：105371及113216）的產品，因為可能有潛在品質問題。衞生署接獲凱健通知，由於受影響批次的產品的持續穩定性檢測結果顯示未能符合品質規格，上述產品的海外製造商正回收上述批次產品。作為預防措施，凱健自願從市面回收上述批次產品。上述三款產品分別含有carbimazole、doxycycline及methyldopa。三款產品均屬處方藥物：carbimazole用於抑制甲狀腺功能亢進患者的甲狀腺素的產生，doxycycline用於治療細菌感染，methyldopa則用於治療高血壓。根據凱健提供的資料，受影響批次曾進口香港，並供應予私家醫生、私家醫院及藥房。凱健已設立熱線電話（3472 8102）解答相關查詢。衞生署至今未有接獲上述批次產品有關的藥物不良反應報告。衞生署會密切監察回收情況。正在服用上述產品的病人不應自行停藥，應盡早向其醫護人員諮詢意見，以作適當安排。

完2026年8月14日（星期五）